Novo Nordisk offers 2 Flagship biotechs up to $1B total for obesity, MASH deals

As part of a pact with Flagship Pioneering, Novo Nordisk has inked separate cardiometabolic disease research deals with two Flagship-founded biotechs that are worth up to $532 million each. 

The freshly formed agreements are with Omega Therapeutics and Cellarity, two Massachusetts biotechs that fall under Flagship’s umbrella. The partnerships are part of a broader ecosystem collaboration Flagship and Novo Nordisk’s Bio Innovation Hub struck up in mid-2022 that aims to quickly build a portfolio of breakthrough medicines for cardiometabolic and rare diseases.